Clarivate (NYSE:CLVT) Hits New 12-Month Low - What's Next?
Clarivate PLC (NYSE:CLVT) recently hit a new 52-week low of $1.47, trading at $1.4650, amidst weak market performance and negative analyst sentiment. The company slightly surpassed EPS expectations but saw a 5.5% year-over-year revenue decline and reported a negative net margin. Insider trading activity was mixed, with a director selling 2.49 million shares and another buying 250,000 shares.
What Does Clarivate (NYSE:CLVT) New Low Signal on NYSE?
Clarivate (NYSE:CLVT) operates in the information services sector, providing data, software, and research tools to academia, life sciences, intellectual property, and government. The article details Clarivate's key products like Web of Science, ProQuest, Ex Libris, and Derwent Innovation, emphasizing their role in research discovery, library management, and intellectual property. It highlights Clarivate's diverse international customer base and its specialized position within the NYSE Composite, focusing on information, digital content, and research technology.
Clarivate (NYSE:CLVT) Stock Falls 5.9% - Here's Why
Clarivate (NYSE:CLVT) shares dropped 5.9% on Friday to $1.51, with significantly lower trading volume than average. The decline comes amidst a "Reduce" consensus rating from analysts, a missed revenue forecast in its latest earnings report despite beating EPS estimates, and a 5.5% year-over-year revenue decrease. Insider activity was mixed, with one director selling a large number of shares while another purchased a substantial amount.
Clarivate : IPfolio Selected by Topcon
Clarivate Plc announced that Topcon Corporation has selected its IPfolio solution for intellectual property management. This move will allow Topcon to transition from an on-premises system to a centralized cloud-based platform, enhancing collaboration between its IP and R&D teams and improving operational efficiency. IPfolio's integration of data, insights, and future AI capabilities aims to help Topcon maximize the value of its IP and accelerate growth.
Clarivate Plc stock hits 52-week low at 1.65 USD By Investing.com
Clarivate Plc's stock has fallen to a new 52-week low of $1.65, marking a nearly 55% decline over the past year. Despite this, InvestingPro data suggests the stock may be undervalued given its impressive gross profit margin of 66.8% and analyst predictions of profitability this year. The company recently reported mixed Q2 2026 results, beating earnings forecasts but slightly missing revenue expectations.
Clarivate Plc stock hits 52-week low at 1.65 USD
Clarivate Plc's stock has fallen to a new 52-week low of $1.66, representing a significant drop of nearly 55% over the past year. Despite this decline and a slight revenue miss in Q2 2026, InvestingPro data suggests the stock may be undervalued, maintaining a strong gross profit margin of 66.8%, with analysts predicting profitability for the year. The company reported adjusted earnings of $0.19 per share, surpassing forecasts, though revenue was slightly below expectations at $587.3 million.
Clarivate (NYSE:CLVT) Hits New 1-Year Low - What's Next?
Clarivate (NYSE:CLVT) shares recently hit a new 52-week low of $1.66, with analysts largely issuing negative ratings and an average price target of $3.02. Despite slightly beating EPS estimates, the company reported a 5.5% year-over-year revenue decline and a negative net margin. Insider activity was mixed, with one director buying shares while another sold a significant stake, reflecting varied confidence in the company's future.
CMNN5201543 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Clarivate Plc 4.875% bond maturing on June 30, 2029 (CMNN5201543). It outlines key facts about the issuer, bond characteristics, and details regarding interest payments and redemption. The bond has a face value of $1,000.00 USD with semi-annual fixed-rate coupon payments.
Clarivate PLC (16A.MU) Stock Price, News, Quote & History
This page provides stock price, news, quote, and historical data for Clarivate PLC (16A.MU). It displays the current stock price, market performance of various indices, and currency exchange rates. The article also mentions premium features for tracking hiring trends and includes general company information.
Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities
Clarivate Plc announced the pricing terms for its cash tender offer to purchase outstanding 3.875% Senior Secured Notes due 2028. The offer includes a $75 million cap on the aggregate principal amount of notes purchased and specifies the total consideration and reference yield. The settlement date is expected to be September 25, 2026, with Citigroup Global Markets Inc. acting as dealer manager.
Clarivate Announces Final Results of Offer to Purchase for Cash Certain of its Outstanding Debt Securities
Clarivate Plc announced the final results of its cash tender offer to purchase up to $75,000,000 aggregate principal amount of its 3.875% Senior Secured Notes due 2028. The offer expired on September 23, 2026, with $665,198,000 aggregate principal amount of Notes tendered, and $75,000,000 accepted for purchase at a proration factor of 11.3%. Holders of accepted Notes will receive an Accrued Coupon Payment on the settlement date of September 25, 2026.
Clarivate Plc Announces Completion and Results of Debt Tender Offer by Subsidiary
Clarivate Plc announced the completion and results of a cash tender offer by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for select debt securities. The details of the offer's expiration and outcome were disclosed in a Form 8-K filing with the SEC on September 24, 2026, with a press release providing specific terms and acceptance rates. Clarivate Plc's principal executive office is in London, UK, and its shares trade on the NYSE under the ticker CLVT.
Clarivate Plc (CLVT) Sets Pricing Terms for $75M Tender of 2028 Notes
Clarivate Plc (CLVT) has announced the pricing terms for a cash tender offer to repurchase its 3.875% Senior Secured Notes due 2028, with a tender cap of $75 million. The settlement is expected on September 25, 2026. This action is described as a mid-cycle liability management strategy aimed at optimizing the company's balance sheet.
Holders tendered $665M in notes to a Clarivate (CLVT) subsidiary. Only a portion was accepted.
Clarivate Science Holdings Corporation, a subsidiary of Clarivate Plc, announced the final results of its cash tender offer for its 3.875% Senior Secured Notes due 2028. The company aimed to purchase up to $75 million in aggregate principal, but received tenders totaling $665.198 million. Consequently, only $75 million was accepted with an 11.3% proration factor, and the remaining tendered notes will be returned to holders.
Clarivate completes $75M tender offer to buy ba...
Clarivate Plc has successfully completed a cash tender offer to repurchase up to $75 million of its 3.875% Senior Secured Notes due 2028. Although $665.2 million of notes were tendered, only the maximum allowed $75 million were accepted due to proration, with the settlement set for September 25, 2026. This action is part of Clarivate's debt management strategy and comes amidst a mixed performance for Financials-sector stocks on Pluang.
Clarivate Plc (CLVT) Finalizes Cash Tender for 2028 Notes Up to $75M
Clarivate Plc (CLVT) has finalized a cash tender offer to purchase up to $75 million of its 3.875% Senior Secured Notes due 2028. The settlement is scheduled for September 25, 2026, with accrued interest to be paid on accepted notes. This move is interpreted as a balance sheet action aimed at managing leverage and maturities.
Clarivate announces tender offer pricing for 2028 notes
Clarivate Plc announced the pricing terms for its cash tender offer to purchase its 3.875% Senior Secured Notes due 2028. The total consideration is set at $975.15 per $1,000 principal amount of notes, with a tender offer cap of $75 million. The offer is set to expire today, September 24, 2026, at 5:00 p.m. New York time.
Form 8K CLARIVATE PLC For: 23 September By Investing.com
This article reports on Clarivate PLC's Form 8K filing for September 23. It notes that the company's stock symbol is CLVT and it saw a minor gain of 0.55%. The content primarily consists of the headline repeated and surrounded by numerous navigation links, ads, and market data from Investing.com.
Clarivate to Report Third Quarter 2026 Results on November 3, 2026
Clarivate Plc announced it will report its third-quarter 2026 financial results before the market opens on Tuesday, November 3, 2026. The company will host a conference call and webcast at 8:30 AM Eastern Time on the same day to discuss the results, which will be accessible via their investor relations website.
Clarivate to Report Third Quarter 2026 Results on November 3, 2026
Clarivate Plc announced that it will report its Third Quarter 2026 financial results on November 3, 2026. The announcement was made through PR Newswire. This brief notice serves to inform stakeholders of the upcoming earnings release.
Clarivate schedules its next results call for Nov. 3
Clarivate Plc (NYSE: CLVT) announced it will report its third-quarter 2026 financial results before the market opens on November 3, 2026. The company will host a conference call and live webcast at 8:30 AM Eastern Time on the same day to review the results, which will be accessible via their investor relations website. A replay of the webcast will be available for one year.
Clarivate to Report Third Quarter 2026 Results on November 3, 2026
Clarivate Plc (NYSE: CLVT) announced it will report its financial results for the third quarter of 2026 before the market opens on Tuesday, November 3, 2026. The company will also host a conference call and webcast at 8:30 AM Eastern Time on the same day to discuss the results. The press release and supporting financial information will be available on Clarivate's investor website.
Clarivate (CLVT) Stock Price, News & Analysis $CLVT
This article provides a comprehensive analysis of Clarivate (CLVT) stock, including its current price, market capitalization, analyst ratings, and key financial metrics. It highlights a consensus "Reduce" rating from analysts with a price target of $3.02, alongside insights into the company's P/B ratio suggesting potential undervaluation. The report also covers short interest, insider trading activity, and recent news headlines related to Clarivate's debt securities offer and AI initiatives.
Clarivate Plc (NYSE:CLVT) Launches Cash Tender for 2028 Notes, Capped at $75M
Clarivate Plc (NYSE:CLVT) has initiated a cash tender offer for its 3.875% Senior Secured Notes due 2028, with the offer capped at $75 million. The pricing for the tender offer will be determined by a fixed spread over a reference yield on September 23, 2026, and the offer is set to expire on the same day, with settlement expected on September 25, 2026. This move is seen as a liability management effort consistent with debt reduction strategies.
Clarivate (CLVT) starts $75M debt buyback
Clarivate Plc announced a cash tender offer through its subsidiary, Clarivate Science Holdings Corporation, to repurchase a portion of its 3.875% Senior Secured Notes due 2028. The offer is capped at $75 million and will expire on September 23, 2026, with settlement expected on September 25, 2026. The Total Consideration will be based on a fixed spread over the yield of a specific U.S. Treasury note.
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
Clarivate Plc has announced its Citation Laureates 2026, honoring 22 researchers whose work is deemed Nobel-class. These individuals, selected by experts at the Institute for Scientific Information, have made pioneering contributions across various fields, including GLP-1 medicines, optical imaging, and gene editing, with 89 past Laureates having gone on to win Nobel Prizes. The program highlights the long-term impact of fundamental research on science and society.
Clarivate launches tender offer for up to $75M of 3.875% secured notes due 2028
Clarivate (CLVT) has initiated a cash tender offer to repurchase up to $75 million of its 3.875% Senior Secured Notes due July 1, 2028. The offer's total consideration per $1,000 will be based on a Reference Yield plus a fixed spread of 50 bps, with the price determined on September 23, 2026. The offer expires on September 23, 2026, and settlement is expected on September 25, 2026.
Clarivate unit launches tender offer for 2028 notes
Clarivate Plc's subsidiary, Clarivate Science Holdings Corporation, has initiated a cash tender offer to repurchase its 3.875% Senior Secured Notes due 2028. The offer has a cap of $75 million on the aggregate principal amount of notes to be purchased, which may be adjusted, and the company may buy up to $825 million in outstanding notes. The total consideration per $1,000 principal amount will be determined based on a fixed spread plus a reference yield, with the offer set to expire on Monday at 5:00 p.m. New York time.
Clarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities
Clarivate Plc announced that its subsidiary, Clarivate Science Holdings Corporation, has launched a cash tender offer to repurchase its 3.875% Senior Secured Notes due 2028, with a Tender Cap of $75,000,000. The offer expires on September 23, 2026, and is managed by Citigroup Global Markets Inc. as the dealer manager and Global Bondholder Services Corporation as the tender and information agent.
Clarivate unit launches tender offer for 2028 notes By Investing.com
Clarivate Plc's subsidiary, Clarivate Science Holdings Corporation, has initiated a cash tender offer to repurchase its 3.875% Senior Secured Notes due 2028. The offer is capped at $75 million in aggregate principal amount, with the total consideration determined by a fixed spread over a U.S. Treasury yield. The tender offer is set to expire on Monday, with settlement expected on Wednesday.
GLP-1s, gene editing make 2026 Citation Laureates list
Clarivate plc has named three key GLP-1 researchers among its 2026 Citation Laureates, recognizing the scientific breakthroughs behind these blockbuster peptide hormones. This acknowledgment comes as the treatment potential for GLP-1 drugs continues to expand beyond traditional metabolic indications. The article also mentions the inclusion of gene editing in the Citation Laureates list.
Clarivate Science Holdings Corporation Initiates Cash Tender Offer for Select Debt Securities
Clarivate Science Holdings Corporation, a wholly-owned subsidiary of Clarivate Plc, has launched a cash tender offer for specific debt securities. This announcement was made on September 17, 2026, via a Form 8-K filing with the SEC. While the filing confirms the tender offer, details regarding the financial terms, pricing, or deadlines are not provided within the main body of the document, instead referring to an attached press release (Exhibit 99.1).
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
Clarivate Plc has announced its 2026 Citation Laureates, honoring 22 researchers whose work is deemed Nobel-class. These individuals, selected by experts at the Institute for Scientific Information (ISI) at Clarivate, have made significant contributions across fields like Physiology or Medicine, Physics, Chemistry, and Economics. Notably, this year's honorees include pioneers behind GLP-1 medicines, optical imaging, and advanced gene editing technologies.
Clarivate Director Cornick Buys 900,000 Shares for $1.7 Million. What Does This Tell Investors About the Outlook for 2026?
Clarivate Plc Director Kenneth L. Cornick purchased 900,000 shares of the company's stock for $1.7 million, increasing his total holdings by 74% to approximately 2.1 million shares. This significant insider buying, executed through Cornick Family Investor, LLC, signals a bullish outlook despite the stock's 52% decline over the past year and analysts' projections of declining sales. Management believes recent restructuring and the sale of non-core divisions will lead to more predictable revenue and long-term growth.
Responsible AI in Digital Collections: Part 1
This article discusses the application of AI-assisted entity extraction in digital collections within libraries, archives, and cultural heritage institutions. It highlights how AI can help uncover hidden relationships and context in digitized materials, improving discoverability for researchers beyond traditional keyword searches. The piece emphasizes that this technology enhances metadata and streamlines workflows for librarians and archivists, allowing for richer research experiences while maintaining human oversight.
Clarivate Director Cornick Buys 900,000 Shares for $1.7 Million. What Does This Tell Investors About the Outlook for 2026?
Clarivate Director Kenneth L. Cornick recently purchased 900,000 shares of Clarivate Plc (NYSE:CLVT) for $1.7 million, increasing his total holdings by 74%. This significant insider purchase suggests a bullish outlook despite the stock's 52% decline over the past year and analyst predictions of declining sales. Management anticipates modest growth of about 2% for 2026 after selling non-core divisions, a strategy Cornick seems to endorse.
Clarivate Director Cornick Buys 900,000 Shares for $1.7 Million. What Does This Tell Investors About the Outlook for 2026?
Clarivate Plc Director Kenneth L. Cornick recently purchased 900,000 shares for $1.7 million, increasing his total equity holdings by 74%. This significant insider purchase, especially after a 52% stock price decline over the past year, signals a bullish outlook despite the company's recent market headwinds and negative net income. While Wall Street analysts project a sales decline, management anticipates modest growth for 2026 after selling non-core divisions, a vision Cornick appears to support with his investment.
AI in healthcare: Are you tracking the right competitors?
This article discusses how patent intelligence can reveal unexpected competitors in the rapidly evolving field of AI in healthcare. It highlights that medical technology companies are leading in AI-related patent filings, and relevant AI capabilities are emerging from diverse industries such as computing and digital platforms, not just traditional life sciences. The author suggests that IP teams should track technologies across industry boundaries to identify potential partners, acquisition targets, or competitive threats early on.
CLVT|Clarivate PLC|Price:1.923|Chg%:-0.037
This article provides a detailed overview of Clarivate PLC (CLVT) stock, including its current price, market capitalization, key financial figures, and recent performance. It also covers analyst ratings, a technical analysis summary, company profile, and major shareholders. The stock's current rating is "Hold" with a target price indicating a significant upside potential.
ETFs Investing in Clarivate PLC Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Clarivate PLC (16A) stocks, providing investors with options to invest in the company indirectly. Each ETF entry includes details such as market value, weight of Clarivate PLC in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, and 3-year NAV total return. The ETFs predominantly focus on small-cap, value, and extended market strategies.
Does Clarivate’s Expanded Agentic AI Across Cortellis Reshape the Bull Case For Clarivate (CLVT)?
Clarivate Plc has expanded agentic AI capabilities across its Cortellis life sciences portfolio, aiming to integrate AI into drug discovery, safety assessment, and portfolio decision workflows. This move seeks to reduce manual effort and support faster, evidence-based decisions, reinforcing Clarivate's investment narrative around workflow integration and efficiency. While this could enhance the bull case, investors should remain aware of potential risks such as competition, pricing pressure, continued net losses, and the company's high debt load.
Is Clarivate (CLVT) Below Fair Value On Its Cortellis Agentic AI Expansion?
Clarivate (CLVT) has expanded its Cortellis portfolio with new agentic AI capabilities aimed at accelerating life sciences R&D, despite its stock experiencing a significant decline. The company's valuation narrative suggests it is undervalued at $2.50 per share compared to its current price of $1.91, emphasizing recurring revenue and future profit potential. However, concerns about higher education budgets and competition from free research data could impact its growth.
Clarivate : and KYBORA Partner to Help Biopharma Companies Execute Strategic Transaction Outcomes
Clarivate and KYBORA have partnered to offer integrated, end-to-end transaction advisory services for bioph
Does Clarivate’s Expanded Agentic AI Across Cortellis Reshape the Bull Case For Clarivate (CLVT)?
Clarivate Plc has expanded its agentic AI capabilities across its Cortellis life sciences portfolio to integrate AI into drug discovery, safety assessment, and portfolio decision workflows. This move aims to reduce manual effort and support faster, evidence-based decisions, reinforcing Clarivate's investment narrative around workflow integration and efficiency. While the AI expansion supports deeper workflow integration, investors should also consider risks such as competition, pricing pressure, continued net losses, and the company's high debt load.
Clarivate (NYSE:CLVT) Shares Gap Up on Insider Buying Activity
Clarivate (NYSE:CLVT) shares gapped up after Director Kenneth L. Cornick purchased 900,000 shares across two transactions totaling approximately $1.67 million. This insider buying activity occurred despite cautious analyst sentiment, with a consensus "Reduce" rating and a price target of $3.02. The company slightly exceeded EPS estimates but reported a 5.5% year-over-year revenue decline.
Clarivate PLC (16A.MU) Analyst Insights, Price Targets & Recommendations
This article provides analyst ratings and price targets for Clarivate PLC (16A.MU). It lists recent "Upgrades & Downgrades" showing various firms maintaining their ratings, including Citigroup, Goldman Sachs, Stifel, and Barclays, with the latest update on July 30, 2026. The stock's current price is 1.6740 EUR.
Kenneth Cornick Acquires 650,000 Shares of Clarivate (NYSE:CLVT) Stock
Clarivate director Kenneth Cornick recently acquired 650,000 shares of NYSE:CLVT stock for approximately $1.21 million, significantly increasing his direct ownership by 59.09% to 1.75 million shares. Despite Clarivate's shares rising 4.4% to $1.90, they remain near their one-year low, and analysts maintain a cautious "Reduce" rating with a $3.02 target price. The company reported a Q2 EPS of $0.19, beating estimates, though revenue declined by 5.5% year-over-year.
Clarivate (NYSE:CLVT) Director Kenneth Cornick Buys 250,000 Shares of Stock
Clarivate (NYSE:CLVT) Director Kenneth Cornick purchased 250,000 shares of the company's stock on August 7th, investing $462,500 at an average price of $1.85 per share. This transaction increased his direct ownership to 2 million shares, a 14.29% increase. Despite the insider buying, analyst sentiment remains cautious, with a consensus "Reduce" rating and a target price of $3.02, following a recent earnings report that showed a 5.5% year-over-year revenue decline.
Enterprise value to EBIT forward of Clarivate Plc – NYSE:CLVT
The article focuses on the enterprise value to EBIT forward for Clarivate Plc (NYSE: CLVT). It presents financial data within the TradingView platform context, highlighting the company's stock information and financial metrics. The primary content available is a data point for this specific financial ratio.
Knowledge graphs: Turning fragmented biomedical data into connected, actionable insight
This article discusses how knowledge graphs address the challenge of fragmented biomedical data, transforming it into actionable insights. It highlights that the problem is not data abundance but usability, with knowledge graphs connecting disparate data points into a unified framework. The piece also explains how Clarivate's AI-powered knowledge graphs are built with trusted data to drive impact across the R&D continuum and make complex information accessible through AI agents.
